首页
/
/
/
微管
/
Sabizabulin
Sabizabulin
{[allProObj[0].p_purity_real_show]}
货号：A1177099
同义名：
VERU-111; ABI-231
Sabizabulin是一种高效、口服可利用的α/β微管蛋白(tubulin)抑制剂，对黑色素瘤和前列腺癌细胞具有强效抗增殖活性（IC50=5.2 nM）。该化合物通过靶向HPV E6和E7抑制肿瘤生长和转移，适用于前列腺癌的研究。
Sabizabulin 化学结构
CAS号：1332881-26-1
Sabizabulin 3D分子结构
CAS号：1332881-26-1
| 规格 |
价格 |
会员价
|
库存 |
数量 |
|
{[ item.pr_size ]}
|
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}
{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]}
{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
|
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}
{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]}
{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
|
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]}
{[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]}
{[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}
|
现货 |
1周
咨询
|
-
+
|
Sabizabulin 纯度/质量文件 产品仅供科研
货号：A1177099
标准纯度：
{[allProObj[0].p_purity_real_show]}
-
全球学术期刊中引用的产品
- • Nature, 2025, 645, 793-800. Ambeed.
[
A201204 ,
A444152 ,
A344107 ,
A952055
]
- • Cell, 2025. Ambeed.
[
A122167
]
- • Science, 2025, 387(6729): eadp5637. Ambeed.
[
A875019
]
- • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed.
[
A104916
]
- • Nat. Nanotechnol., 2025. Ambeed.
[
A243018 ,
A1216705 ,
A522597 ,
A125401 ,
A1355641
]
- 更多 >
Sabizabulin 质控信息
Sabizabulin 细胞实验
|
Cell Line
|
Concentration |
Treated Time |
Description |
References |
| A549/TxR |
4 nM and 16 nM |
10 days |
VERU-111 retained its ability to inhibit colony formation in A549/TxR cells, while paclitaxel and colchicine were ineffective. |
Cancer Lett. 2020 Dec 28;495:76-88 |
| A549 |
4 nM and 16 nM |
10 days |
VERU-111 inhibited colony formation in A549 cells, with almost complete inhibition at 16 nM concentration. |
Cancer Lett. 2020 Dec 28;495:76-88 |
| HeLa cells |
5-80 nM |
24, 48 and 72 hours |
VERU-111 inhibited the proliferation and clonogenic potential of HeLa cells. |
Cancer Lett. 2020 Feb 1;470:64-74 |
| SiHa cells |
5-80 nM |
24, 48 and 72 hours |
VERU-111 inhibited the proliferation and clonogenic potential of SiHa cells. |
Cancer Lett. 2020 Feb 1;470:64-74 |
| CaSki cells |
5-80 nM |
24, 48 and 72 hours |
VERU-111 inhibited the proliferation and clonogenic potential of CaSki cells. |
Cancer Lett. 2020 Feb 1;470:64-74 |
| A549/TxR |
25 nM |
36 hours |
VERU-111 significantly inhibited the migration of A549/TxR cells, while paclitaxel and colchicine were ineffective. |
Cancer Lett. 2020 Dec 28;495:76-88 |
| A549 |
25 nM |
36 hours |
VERU-111 significantly inhibited the migration of A549 cells, with efficacy comparable to paclitaxel. |
Cancer Lett. 2020 Dec 28;495:76-88 |
| SKBR3 |
low nanomolar IC50 values |
72 hours or 96 hours |
Inhibits proliferation of HER2+ breast cancer cells, induces apoptosis |
Cancers (Basel). 2022 Oct 29;14(21):5336 |
| BT474 |
low nanomolar IC50 values |
72 hours or 96 hours |
Inhibits proliferation of HER2+ breast cancer cells, induces apoptosis |
Cancers (Basel). 2022 Oct 29;14(21):5336 |
|
Sabizabulin 动物实验
|
Species
|
Animal Model
|
Administration |
Dosage |
Frequency |
Description |
References |
| Zebrafish |
Zebrafish embryos |
Immersion |
0.2 μM |
48 hours |
To evaluate the toxic effects of Sabizabulin on zebrafish embryonic development, showing 20% mortality at clinically relevant concentrations. |
Sci Rep. 2023 Oct 9;13(1):17037 |
| NSG mice |
BT474 xenograft model |
Oral |
17 mg/kg |
3 times per week for 33 days |
Inhibits HER2+ breast cancer tumor growth and metastasis |
Cancers (Basel). 2022 Oct 29;14(21):5336 |
| Athymic nude mice |
Orthotopic xenograft model of cervical cancer |
Intratumoral injection |
50 μg/mice |
Three times per week for three weeks |
VERU-111 significantly inhibited the growth of orthotopic xenograft tumors of cervical cancer. |
Cancer Lett. 2020 Feb 1;470:64-74 |
| Female athymic nude mice |
A549 xenograft model |
Oral |
7.5 mg/kg and 12.5 mg/kg |
5 days per week, continuous treatment |
VERU-111 significantly inhibited tumor growth in the A549 xenograft model, with efficacy comparable to paclitaxel. |
Cancer Lett. 2020 Dec 28;495:76-88 |
|
Sabizabulin 实验方案
| 计算器 |
|
| 存储液制备 |
 |
1mg |
5mg |
10mg |
|
1 mM
5 mM
10 mM
|
2.65mL
0.53mL
0.26mL
|
13.25mL
2.65mL
1.32mL
|
26.50mL
5.30mL
2.65mL
|
Sabizabulin 技术信息
搜索
